NIAMS

Name

NIAMS

Legal name

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Website

https://www.niams.nih.gov

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Government Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Educational Support Services (611710)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYHLAJAIAA

National Public Health Reference Laboratories

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

• Biomedical research institute
• Arthritis and musculoskeletal research
• Skin disease research
• Clinical trials program
• Research grant funding

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Federal Appropriations: NIAMS receives annual congressional appropriations through the National Institutes of Health (NIH) to support medical research, training scientists and clinicians, and communicating research progress on arthritis, musculoskeletal, and skin diseases.

Distribution channels4 records

Marketing channels6 records

Core offering

NIAMS is a U.S. federal research institute that supports and conducts basic, translational, and clinical research on arthritis, musculoskeletal, and skin diseases. It distributes extramural research grants to universities, hospitals, and medical schools, operates intramural labs and core facilities at the NIH campus, runs clinical trials at the NIH Clinical Center, and publishes free health information and educational resources for the public.

Product overview

NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) is a U.S. government research institute within the NIH that provides health information resources and conducts research rather than commercial products. The organization's offerings include a comprehensive Health Information Portal covering arthritis, musculoskeletal, and skin diseases; an Educational Resources program for K-6 students and teachers; the Extramural Research Program funding external researchers; and a Clinical Research Program conducting studies at the NIH Clinical Center. NIAMS also maintains a Spanish-language portal for Spanish-speaking audiences.

Differentiator

Problem solved

Functional benefit

Products and services

• NIAMS Health Information Portal Comprehensive online portal providing health information, educational resources, and clinical trial information about arthritis, musculoskeletal diseases, and skin conditions for patients, healthcare providers, and researchers.
• Educational Resources for Students and Teachers Science-based classroom materials and activities about bones, joints, muscles, and skin for students in grades 4-6, aligned with Next Generation Science Standards and National Health Education Standards, including Kahoot! quizzes.
• NIAMS Extramural Research Program Grant funding program supporting basic, translational, and clinical research studies and training in arthritis, musculoskeletal, and skin diseases through universities, hospitals, and research organizations. Approximately 1,500 extramural grants and cooperative agreements supported annually with over $500 million in funding.
• NIAMS Clinical Research Program Clinical studies and natural history observational studies conducted at the NIH Clinical Center focusing on autoimmune diseases, lupus, vasculitis, myositis, and skin conditions for enrolled patients.
• NIAMS Spanish Language Portal Spanish-language version of the NIAMS health information portal providing access to health topics, disease information, and resources in Spanish.

Quantifiable outcome

• Over $500 million in annual funding distributed across 1,500 extramural grants
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered minor and core.

• National Research Network on Autoimmune Diseases ExposomeminorStrategic or Co-development Partner · 1 March 2024New awardees developing a national research network to explore the role of the exposome in autoimmune diseases, expanding research in an emerging area critical to human health.
• Accelerating Medicines Partnership (AMP)coreStrategic or Co-development PartnerNIH, pharmaceutical companies, and nonprofit organizations created the Accelerating Medicines Partnership to develop new ways of identifying and validating promising biological targets for diagnostics and drug development. NIAMS participates in multiple AMP programs designed to accelerate the development of therapies for autoimmune diseases.
• Back Pain Consortium (BACPAC) Research ProgramcoreStrategic or Co-development PartnerBACPAC is a translational, patient-centered effort to address the need for effective and personalized therapies for chronic low back pain within the NIH HEAL Initiative. It examines biomedical mechanisms within a biopsychosocial context using interdisciplinary methods and innovative technologies.
• Osteoarthritis Initiative (OAI)coreStrategic or Co-development PartnerMulticenter, longitudinal, prospective observational study of knee osteoarthritis. Public-private partnership between NIH and private industry seeking to improve diagnosis and monitoring of OA and foster development of new treatments.
• Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC)coreStrategic or Co-development PartnerNIH Common Fund program that aims to extensively catalogue the biological molecules affected by physical activity in people, identify key molecules underlying systemic effects of physical activity, and characterize their function to understand how exercise translates into better health.
• Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN)coreStrategic or Co-development PartnerConsortium that defines the innervation of different articular and peri-articular tissues in joints by sensory neurons that mediate pain sensation. Part of the NIH HEAL Initiative to identify novel targets for reducing pain.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/NIAMSNIH
• Facebookfacebook.com/NIH.NIAMS
• LinkedInlinkedin.com/company/national-institute-of-arthritis-and-musculoskeletal-and-skin-disease-niams

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments22 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIAMS